Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication.

Sublingual (s.l.) vaccination is an efficient way to induce elevated levels of systemic and mucosal immune responses. To mediate mucosal uptake, ovalbumin (OVA) was genetically fused to adenovirus 2 fiber protein (OVA-Ad2F) to assess whether s.l. immunization was as effective as an alternative route of vaccination. Ad2F-delivered vaccines were efficiently taken up by dendritic cells and migrated mostly to submaxillary gland lymph nodes, which could readily stimulate OVA-specific CD4(+) T cells. OVA-Ad2F + cholera toxin (CT)-immunized mice elicited significantly higher OVA-specific serum IgG, IgA and mucosal IgA antibodies among the tested immunization groups. These were supported by elevated OVA-specific IgG and IgA antibody-forming cells. A mixed T(h)-cell response was induced as evident by the enhanced IL-4, IL-10, IFN-γ and TNF-α-specific cytokine-forming cells. To assess whether this approach can stimulate neutralizing antibodies, immunizations were performed with the protein encumbering the β-trefoil domain of C-terminus heavy chain (Hcβtre) from botulinum neurotoxin A (BoNT/A) as well as when fused to Ad2F. Hcβtre-Ad2F + CT-dosed mice showed the greatest serum IgG, IgA and mucosal IgA titers among the immunization groups. Hcβtre-Ad2F alone also induced elevated antibody production in contrast to Hcβtre alone. Plasma from Hcβtre + CT- and Hcβtre-Ad2F + CT-immunized groups neutralized BoNT/A and protected mice from BoNT/A intoxication. Most importantly, Hcβtre-Ad2F + CT-immunized mice were protected from BoNT/A intoxication relative to Hcβtre + CT-immunized mice, which only showed ∼60% protection. This study shows that s.l. immunization with Ad2F-based vaccines is effective in conferring protective immunity.

[1]  M. Caminati,et al.  Immune Mechanisms of Allergen-Specific Immunotherapy , 2012 .

[2]  C. Czerkinsky,et al.  Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. , 2012, Current topics in microbiology and immunology.

[3]  M. Maddaloni,et al.  Mucosal Targeting of a BoNT/A Subunit Vaccine Adjuvanted with a Mast Cell Activator Enhances Induction of BoNT/A Neutralizing Antibodies in Rabbits , 2011, PloS one.

[4]  M. Maddaloni,et al.  Adenovirus F protein as a delivery vehicle for botulinum B , 2010, BMC Immunology.

[5]  Irina A. Kochetkova,et al.  IL-35 Stimulation of CD39+ Regulatory T Cells Confers Protection against Collagen II-Induced Arthritis via the Production of IL-10 , 2010, The Journal of Immunology.

[6]  B. Poulain [Botulinum neurotoxin]. , 2010, Revue neurologique.

[7]  J. Schiller,et al.  Sublingual Immunization with Nonreplicating Antigens Induces Antibody-Forming Cells and Cytotoxic T Cells in the Female Genital Tract Mucosa and Protects against Genital Papillomavirus Infection1 , 2009, The Journal of Immunology.

[8]  Leonard A. Smith,et al.  Botulinum Neurotoxin Vaccines: Past history and recent developments , 2009, Human vaccines.

[9]  Leonard A. Smith Botulism and vaccines for its prevention. , 2009, Vaccine.

[10]  R. Rappuoli,et al.  Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin , 2009, PloS one.

[11]  M Landi,et al.  The safety of sublingual immunotherapy with one or multiple pollen allergens in children , 2008, Allergy.

[12]  Leonard A. Smith,et al.  An alternative approach to combination vaccines: intradermal administration of isolated components for control of anthrax, botulism, plague and staphylococcal toxic shock , 2008, Journal of immune based therapies and vaccines.

[13]  Zhongxia Li,et al.  Novel Vaccination Protocol with Two Live Mucosal Vectors Elicits Strong Cell-Mediated Immunity in the Vagina and Protects against Vaginal Virus Challenge1 , 2008, The Journal of Immunology.

[14]  C. Czerkinsky,et al.  Sublingual vaccination with influenza virus protects mice against lethal viral infection , 2008, Proceedings of the National Academy of Sciences.

[15]  Shuang Wang,et al.  Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A. , 2007, Vaccine.

[16]  C. Czerkinsky,et al.  Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. , 2007, Vaccine.

[17]  Eric A. Johnson,et al.  Subunit Vaccine against the Seven Serotypes of Botulism , 2007, Infection and Immunity.

[18]  H. Malling,et al.  Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. , 2007, The Journal of allergy and clinical immunology.

[19]  Leonard A. Smith,et al.  Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. , 2007, Vaccine.

[20]  S. Cai,et al.  Strategies to design inhibitors of Clostridium botulinum neurotoxins. , 2007, Infectious disorders drug targets.

[21]  P. Doherty,et al.  Mucosal HIV-1 Pox Virus Prime-Boost Immunization Induces High-Avidity CD8+ T Cells with Regime-Dependent Cytokine/Granzyme B Profiles1 , 2007, The Journal of Immunology.

[22]  G. Canonica,et al.  Sublingual immunotherapy: update 2006 , 2006, Current opinion in allergy and clinical immunology.

[23]  J. Mcghee,et al.  Mucosal Vaccine Targeting Improves Onset of Mucosal and Systemic Immunity to Botulinum Neurotoxin A1 , 2006, The Journal of Immunology.

[24]  S. Durham,et al.  Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. , 2006, Journal of Allergy and Clinical Immunology.

[25]  G. Canonica,et al.  Sublingual immunotherapy in the treatment of adult allergic rhinitis patients , 2006, Allergy.

[26]  Leonard A. Smith,et al.  Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. , 2006, Toxicon : official journal of the International Society on Toxinology.

[27]  S. Elliott,et al.  Botulism: the many faces of botulinum toxin and its potential for bioterrorism. , 2006, Infectious disease clinics of North America.

[28]  P. Moingeon,et al.  Immune mechanisms of allergen‐specific sublingual immunotherapy , 2006, Allergy.

[29]  M. Lynch,et al.  Proinflammatory responses in the murine brain after intranasal delivery of cholera toxin: implications for the use of AB toxins as adjuvants in intranasal vaccines. , 2005, The Journal of infectious diseases.

[30]  J. Bienenstock,et al.  Bronchus‐ and nasal‐associated lymphoid tissues , 2005, Immunological reviews.

[31]  Jan Holmgren,et al.  Mucosal immunity and vaccines , 2005, Nature Medicine.

[32]  S. Durham,et al.  Sublingual immunotherapy for allergic rhinitis: systematic review and meta‐analysis * , 2005, Allergy.

[33]  G. Passalacqua,et al.  Safety of sublingual immunotherapy with a monomeric allergoid in very young children , 2005, Allergy.

[34]  R. Fimmers,et al.  Asymptomatic atopy is associated with increased indoleamine 2,3‐dioxygenase activity and interleukin‐10 production during seasonal allergen exposure , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[35]  R. Couch Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. , 2004, The New England journal of medicine.

[36]  Robert T. Chen,et al.  Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. , 2004, The New England journal of medicine.

[37]  G. Canonica,et al.  Sublingual immunotherapy: an update , 2004, Current opinion in allergy and clinical immunology.

[38]  L. Simpson,et al.  Identification of the major steps in botulinum toxin action. , 2004, Annual review of pharmacology and toxicology.

[39]  E. Kunkel,et al.  Plasma-cell homing , 2003, Nature Reviews Immunology.

[40]  G. Nabel,et al.  Enhanced Mucosal Immunoglobulin A Response of Intranasal Adenoviral Vector Human Immunodeficiency Virus Vaccine and Localization in the Central Nervous System , 2003, Journal of Virology.

[41]  T. Bieber,et al.  Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. , 2003, The Journal of allergy and clinical immunology.

[42]  T. Macdonald The mucosal immune system , 2003, Parasite immunology.

[43]  N. Fairweather,et al.  Vaccination against type F botulinum toxin using attenuated Salmonella enterica var Typhimurium strains expressing the BoNT/F H(C) fragment. , 2003, Vaccine.

[44]  D. Pascual,et al.  Absence of L-Selectin Delays Mucosal B Cell Responses in Nonintestinal Effector Tissues1 , 2002, The Journal of Immunology.

[45]  P. Rufin,et al.  Safety of Various Dosage Regimens during Induction of Sublingual Immunotherapy , 2002, International Archives of Allergy and Immunology.

[46]  K. Acharya,et al.  Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. , 2002, Trends in biochemical sciences.

[47]  Jie Zhang,et al.  Oral Mucosal Drug Delivery , 2002, Clinical pharmacokinetics.

[48]  J. Holmgren,et al.  Nasal and Vaginal Vaccinations Have Differential Effects on Antibody Responses in Vaginal and Cervical Secretions in Humans , 2001, Infection and Immunity.

[49]  N. Walters,et al.  Cutting Edge: Dichotomy of Homing Receptor Dependence by Mucosal Effector B Cells: αE Versus L-Selectin1 , 2001, The Journal of Immunology.

[50]  N. Walters,et al.  Impaired Mucosal Immunity in L-Selectin-Deficient Mice Orally Immunized with a Salmonella Vaccine Vector1 , 2001, The Journal of Immunology.

[51]  J. Mcghee,et al.  Oral Tolerance Revisited: Prior Oral Tolerization Abrogates Cholera Toxin-Induced Mucosal IgA Responses1 , 2001, The Journal of Immunology.

[52]  Gerhard Walzl,et al.  Mucosal Delivery of a Respiratory Syncytial Virus CTL Peptide with Enterotoxin-Based Adjuvants Elicits Protective, Immunopathogenic, and Immunoregulatory Antiviral CD8+ T Cell Responses1 , 2001, The Journal of Immunology.

[53]  A. Frew,et al.  Sublingual immunotherapy. , 2008, The New England journal of medicine.

[54]  J. Mcghee,et al.  Cutting Edge: The Mucosal Adjuvant Cholera Toxin Redirects Vaccine Proteins into Olfactory Tissues , 2000, The Journal of Immunology.

[55]  Č. Venclovas,et al.  Structure‐based sequence alignment for the β‐trefoil subdomain of the clostridial neurotoxin family provides residue level information about the putative ganglioside binding site , 2000, FEBS letters.

[56]  L. Smith,et al.  Development of vaccines for prevention of botulism. , 2000, Biochimie.

[57]  S. Swaminathan,et al.  Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B , 2000, Nature Structural Biology.

[58]  J. Middlebrook,et al.  Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A. , 2000, Vaccine.

[59]  Leonard A. Smith,et al.  Purification, Potency, and Efficacy of the Botulinum Neurotoxin Type A Binding Domain from Pichia pastoris as a Recombinant Vaccine Candidate , 1998, Infection and Immunity.

[60]  D. Swerdlow,et al.  Botulism in the United States: A Clinical and Epidemiologic Review , 1998, Annals of Internal Medicine.

[61]  W. C. Stewart,et al.  Beta-blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse events. , 1998, Archives of internal medicine.

[62]  A. B. Maksymowych,et al.  Induction of an immune response by oral administration of recombinant botulinum toxin , 1997, Infection and immunity.

[63]  Cleary Jf Pharmacokinetic and pharmacodynamic issues in the treatment of breakthrough pain. , 1997 .

[64]  J. Holmgren,et al.  Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina , 1997, Infection and immunity.

[65]  E. Butcher,et al.  Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. , 1997, The Journal of clinical investigation.

[66]  J. Cleary Pharmacokinetic and pharmacodynamic issues in the treatment of breakthrough pain. , 1997, Seminars in oncology.

[67]  B. Spangler,et al.  Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. , 1992, Microbiological reviews.

[68]  C. Hatheway,et al.  Toxigenic clostridia , 1990, Clinical Microbiology Reviews.

[69]  Robert Johnson,et al.  Structural Analysis , 2020, Multiphysics Modeling with Application to Biomedical Engineering.

[70]  L. Simpson Molecular pharmacology of botulinum toxin and tetanus toxin. , 1986, Annual review of pharmacology and toxicology.

[71]  G. Sakaguchi Clostridium botulinum toxins. , 1982, Pharmacology & therapeutics.

[72]  F. J. Bourne The Mucosal Immune System , 1981, Current Topics in Veterinary Medicine and Animal Science.